179 related articles for article (PubMed ID: 34513685)
1. Integrative Analysis Identified MCT4 as an Independent Prognostic Factor for Bladder Cancer.
Zhao Y; Zhao B; Yan WH; Xia Y; Wang ZH; Zheng GY; Wang WD; Zhang YS
Front Oncol; 2021; 11():704857. PubMed ID: 34513685
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
3. MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma.
Fisel P; Stühler V; Bedke J; Winter S; Rausch S; Hennenlotter J; Nies AT; Stenzl A; Scharpf M; Fend F; Kruck S; Schwab M; Schaeffeler E
Oncotarget; 2015 Oct; 6(31):30615-27. PubMed ID: 26384346
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma.
Cheng B; Chen X; Li Y; Huang X; Yu J
Oncol Rep; 2018 Nov; 40(5):2906-2915. PubMed ID: 30226548
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
Todenhöfer T; Seiler R; Stewart C; Moskalev I; Gao J; Ladhar S; Kamjabi A; Al Nakouzi N; Hayashi T; Choi S; Wang Y; Frees S; Daugaard M; Oo HZ; Fisel P; Schwab M; Schaeffeler E; Douglas J; Hennenlotter J; Bedke J; Gibb EA; Fazli L; Stenzl A; Black PC
Mol Cancer Ther; 2018 Dec; 17(12):2746-2755. PubMed ID: 30262589
[TBL] [Abstract][Full Text] [Related]
6. High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer.
Tong YH; Hu XP; Xiang XP; Fang L
Transl Cancer Res; 2021 Mar; 10(3):1336-1345. PubMed ID: 35116459
[TBL] [Abstract][Full Text] [Related]
7. Lactate Transporter SLC16A3 (MCT4) as an Onco-Immunological Biomarker Associating Tumor Microenvironment and Immune Responses in Lung Cancer.
Tao Q; Li X; Zhu T; Ge X; Gong S; Guo J; Ma R
Int J Gen Med; 2022; 15():4465-4474. PubMed ID: 35509603
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.
Gerlinger M; Santos CR; Spencer-Dene B; Martinez P; Endesfelder D; Burrell RA; Vetter M; Jiang M; Saunders RE; Kelly G; Dykema K; Rioux-Leclercq N; Stamp G; Patard JJ; Larkin J; Howell M; Swanton C
J Pathol; 2012 Jun; 227(2):146-56. PubMed ID: 22362593
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder.
Choi JW; Kim Y; Lee JH; Kim YS
Urology; 2014 Jul; 84(1):245.e9-15. PubMed ID: 24857275
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-induced RelA/p65 derepresses SLC16A3 (MCT4) by downregulating ZBTB7A.
Choi SH; Kim MY; Yoon YS; Koh DI; Kim MK; Cho SY; Kim KS; Hur MW
Biochim Biophys Acta Gene Regul Mech; 2019 Aug; 1862(8):771-785. PubMed ID: 31271899
[TBL] [Abstract][Full Text] [Related]
11. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.
Witkiewicz AK; Whitaker-Menezes D; Dasgupta A; Philp NJ; Lin Z; Gandara R; Sneddon S; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Cell Cycle; 2012 Mar; 11(6):1108-17. PubMed ID: 22313602
[TBL] [Abstract][Full Text] [Related]
12. Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy.
Chen HL; OuYang HY; Le Y; Jiang P; Tang H; Yu ZS; He MK; Tang YQ; Shi M
Cancer Med; 2018 Nov; 7(11):5339-5350. PubMed ID: 30306706
[TBL] [Abstract][Full Text] [Related]
13. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma.
Ohno A; Yorita K; Haruyama Y; Kondo K; Kato A; Ohtomo T; Kawaguchi M; Marutuska K; Chijiiwa K; Kataoka H
Liver Int; 2014 Jul; 34(6):942-52. PubMed ID: 24433439
[TBL] [Abstract][Full Text] [Related]
15. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
[TBL] [Abstract][Full Text] [Related]
16. Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.
Kim Y; Choi JW; Lee JH; Kim YS
Hum Pathol; 2015 Jan; 46(1):104-12. PubMed ID: 25456395
[TBL] [Abstract][Full Text] [Related]
17. Monocarboxylate Transporter 4 (MCT4) Overexpression Is Correlated with Poor Prognosis of Osteosarcoma.
Liu Y; Sun X; Huo C; Sun C; Zhu J
Med Sci Monit; 2019 Jun; 25():4278-4284. PubMed ID: 31177263
[TBL] [Abstract][Full Text] [Related]
18. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Monocarboxylate Transporter 4 in Inflammatory Bowel Disease and Its Potential Use as a Diagnostic Marker.
He L; Wang H; Zhang Y; Geng L; Yang M; Xu Z; Zou K; Xu W; Gong S
Dis Markers; 2018; 2018():2649491. PubMed ID: 29854024
[TBL] [Abstract][Full Text] [Related]
20. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
